Oryzon Advances LSD1 Inhibitor Study in SCLC with Yale Collaboration
Event summary
- Oryzon Genomics initiated a Phase Ib investigator-initiated trial combining iadademstat, radiotherapy, and atezolizumab for extensive stage small cell lung cancer (ES-SCLC).
- The trial, led by Yale University (NCT07113691), will enroll patients with progressive or recurrent ES-SCLC who have previously received platinum-based chemotherapy.
- The study aims to evaluate safety, tolerability, and efficacy, utilizing paired biopsies to analyze tumor and microenvironment changes.
- Dr. Anne Chiang at Yale University is the Principal Investigator for the study.
The big picture
Small cell lung cancer remains a challenging oncology indication with limited treatment options and a high mortality rate. Oryzon's strategy of combining its LSD1 inhibitor, iadademstat, with established therapies like atezolizumab and radiotherapy represents a targeted approach to address this unmet need. The reliance on investigator-initiated trials allows Oryzon to explore novel combinations with lower upfront investment, but also introduces dependencies on external researchers and potentially slower development timelines.
What we're watching
- Clinical Efficacy
- The trial's early data will be crucial in determining whether the combination of iadademstat, radiotherapy, and atezolizumab demonstrates meaningful clinical benefit in a heavily pre-treated ES-SCLC population, given the aggressive nature of the disease.
- Biomarker Identification
- The paired biopsy approach employed by Yale University could yield valuable insights into predictive biomarkers, potentially guiding patient selection and optimizing treatment strategies for iadademstat in SCLC.
- Regulatory Pathway
- Success in this investigator-initiated trial, particularly if it reveals a clear efficacy signal, could accelerate Oryzon's plans to pursue a larger, company-sponsored clinical trial and ultimately influence the regulatory pathway for iadademstat in SCLC.
Related topics